Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.24 per share a year ago.
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After reaching an important support level, CryoPort, Inc. (CYRX) could be a good stock pick from a technical perspective. CYRX recently experienced a "golden cross" event, which saw its 50-day simple
Cryoport, Inc. (NASDAQ:CYRX ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Shelton - Chief Executive Officer Robert Stefan

New Strong Sell Stocks for August 21st

09:01am, Monday, 21'st Aug 2023
ALPMY, CYRX and DRCT have been added to the Zacks Rank #5 (Strong Sell) List on August 21, 2023.
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.17 per share a year ago.
Cryoport released preliminary Q2 results, projecting sales to fall behind The Street's estimates. Lower demand for Cryoport's capital equipment and delays in initiating clinical trials are key reasons

Why Shares of Cryoport are Tumbling Thursday

11:17am, Thursday, 13'th Jul 2023
Cryoport downgraded annual guidance. The company has seen a slowdown in orders from gene therapy and cell therapy clients.

Why Is CryoPort (CYRX) Stock Down 26% Today?

09:04am, Thursday, 13'th Jul 2023
CryoPort (NASDAQ: CYRX ) stock is falling on Thursday after the cell and gene therapy products company released preliminary results for the second quarter of 2023. The bad news for investors in CYRX s

Cryoport shares slide 29% after revenue warning

08:07am, Thursday, 13'th Jul 2023
Shares of Cryoport Inc. CYRX, +3.58% fell 29% in premarket trading on Thursday after the life-science logistics company issued a revenue warning, noting weaker than expected global demand for capital
Cryoport, Inc. is well-positioned to benefit from the growth in the cell and gene therapy industry due to its dominant position in the cold-chain logistics market and potential for substantial revenue
Cryoport, Inc. (NASDAQ:CYRX ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Shelton - Chief Executive Officer Robert Stefanovich
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.31 per share a year ago.
Cryoport, Inc. (NASDAQ:CYRX ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chief Executive Officer Robert St
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE